Edolar Fort

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Edolar Fort

Quick Facts

Property Description
Active ingredient Etodolac
Form Oral formulation (Tablet or capsule)
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID)
Common use Relief from pain and inflammation
Origin Synthetic compound

What Type of Medicine is Edolar Fort?

Edolar Fort is a pharmaceutical preparation whose active component is Etodolac, classified as a Non-steroidal Anti-inflammatory Drug (NSAID). This systemic medication is utilized to address symptoms of pain and inflammation throughout the body.

Etodolac belongs to the pyranocarboxylic acid derivative group of NSAIDs, which distinguishes its specific chemical profile. The overall purpose of this drug entity is to intervene in inflammatory processes. This classification is clinically recognized for providing both analgesic (pain-relieving) and anti-inflammatory effects, supporting its use in conditions associated with swelling and stiffness.

Etodolac: Composition, Form, and Origin

The composition of Edolar Fort relies on the single therapeutic agent, Etodolac. This compound is a synthetic compound, manufactured in a laboratory, and is administered as a single-agent product. The drug is typically presented as an oral formulation, such as a tablet or capsule, intended for oral administration.

This method ensures that Etodolac is absorbed into the bloodstream to produce a systemic effect, managing pain and inflammation in widespread musculoskeletal sites. Pharmacological studies confirm that Etodolac functions as an anti-inflammatory and analgesic agent through the reversible inhibition of cyclooxygenase enzymes. This mechanism helps control the production of the body's chemical mediators that cause swelling and pain.

What is the General Therapeutic Purpose of Edolar Fort?

The general purpose of Edolar Fort is to provide effective symptomatic relief by mitigating both pain and inflammation. By limiting the synthesis of prostaglandins, the drug provides a combined effect: reducing the physical symptoms of swelling and stiffness, and simultaneously reducing the sensation of pain. This integrated functionality means the medication's essential benefit is the management of discomfort associated with various conditions where inflammation is a primary contributing factor.

Regulatory References

  1. Etodolac - DailyMed

What side effects are possible with Edolar Fort?

Edolar Fort belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) and carries mandatory warnings concerning the risk of serious side effects as documented by regulatory bodies.

Serious Adverse Reactions (Boxed Warnings)

Regulatory sources highlight two primary, potentially fatal risks associated with this class of medication, which can occur early in treatment:

  • Cardiovascular Thrombotic Events: Use may increase the risk of serious, potentially fatal cardiovascular events, including myocardial infarction (heart attack) and stroke. The risk is increased with longer use and higher doses. This medication is contraindicated for use immediately before or after coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal (GI) Adverse Events: NSAIDs increase the risk of serious GI inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur without warning, and the risk is generally greater in older adults and those with a history of GI disease.

Other Documented Safety Information

System-Organ Class Common Adverse Reactions Clinically Significant Risks
Gastrointestinal Nausea, vomiting, dyspepsia, abdominal pain, flatulence. Severe GI bleeding, ulceration, and perforation.
Nervous System Headache, dizziness, tinnitus (ringing in the ears). Impaired alertness, difficulty concentrating.
Dermatologic Rash, itching. Serious skin reactions, including exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS.
Hepatic & Renal Liver problems (potentially serious), kidney toxicity, fluid retention (edema).

Population-Specific Safety Considerations

Pregnancy: The use of NSAIDs at 20 weeks gestation and later in pregnancy can cause serious fetal renal dysfunction leading to low amniotic fluid (oligohydramnios) and potential complications. Use during the third trimester carries a risk of premature closure of the fetal ductus arteriosus.

Older Adults: This population is at a greater risk for serious GI adverse events. Monitoring for signs of bleeding, kidney problems, and heart failure is advised during therapy. Concomitant use with alcohol is discouraged as it further increases the risk of GI bleeding.

Overdose and Emergency Response

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Manifestations typically include gastrointestinal effects (nausea, vomiting, epigastric pain) and Central Nervous System (CNS) effects (lethargy, drowsiness, headache, tinnitus, and disorientation). Blurred vision may also be observed.
Serious / life-threatening outcomes The risk of severe gastrointestinal hemorrhage (GI bleeding) is documented. Other serious outcomes include acute renal failure, metabolic acidosis, hypotension, and, rarely, coma or convulsions.
Population-specific overdose notes Increased severity and risk of outcomes are noted in the elderly population. Individuals with pre-existing hepatic or renal impairment may also be at higher risk for severe systemic effects.
When immediate medical help is required Seek immediate medical attention or contact emergency services immediately upon suspected overdose due to the potential for delayed onset of serious or life-threatening complications.

Overdose Management (Official Guidance)

Classification Official Regulatory Statement
Antidote Information No specific antidote is known for Etodolac overdose.
Supportive Management Treatment is limited to symptomatic and supportive care. Decontamination procedures, such as administering activated charcoal, may be considered within one hour of ingestion, along with managing hypotension or metabolic acidosis if required.
Monitoring Requirements Close clinical monitoring of vital signs and laboratory parameters is necessary, and hospitalization is often required for observation.

Connection to the overall overdose profile (2–4 sentences): The official regulatory profile for Etodolac establishes that common overdose presentations involve GI and CNS effects, but mandates urgent action due to the potential for severe outcomes like acute renal failure and GI hemorrhage. Since no specific antidote is known, the required management centers on prompt medical intervention, symptomatic support, and close clinical observation.

Therapeutic Uses of Edolar Fort

Edolar Fort is applied across domains where additional symptomatic support is needed, focusing on managing symptoms related to physical discomfort and inflammatory or irritative states. Its active component may assist with easing symptoms related to pain, tenderness, swelling, and stiffness associated with specific inflammatory conditions. It is used in situations involving certain distressing symptoms that create noticeable physiological strain.

The medication is commonly used across conditions presenting with episodic or fluctuating manifestations, such as osteoarthritis and rheumatoid arthritis, and is relevant for easing symptoms associated with acute pain or musculoskeletal strains.

“It helps address symptom clusters that may become intense or disruptive, such as those associated with acute episodic changes.”

It is often used when symptoms intensify and supportive relief is needed, assisting with maintaining functional stability during symptomatic periods. This contributes to easing the overall symptom load and helps improve day-to-day comfort.

Quick Fact: Focus on Symptoms Related to Inflammatory States

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Edolar Fort is an NSAID (Nonsteroidal Anti-inflammatory Drug), and its use is strictly governed by regulatory documentation defining eligible and contraindicated patient populations.

Populations Who Must Not Use Edolar Fort (Contraindicated)

Official labeling designates the following conditions and patient groups as absolute contraindications:

  • Hypersensitivity: Individuals with a known allergic reaction or hypersensitivity to the drug, aspirin, or any other NSAID.
  • Gastrointestinal Risk: Patients with a history of recurrent or active gastrointestinal ulceration, bleeding, or hemorrhage.
  • Cardiovascular Risk: Patients who have recently undergone (or are about to undergo) Coronary Artery Bypass Graft (CABG) surgery. Also contraindicated in severe heart failure (NYHA Class IV).
  • Organ Impairment: Patients with confirmed severe renal impairment (e.g., creatinine clearance < 30 mL/min) or severe hepatic impairment.
  • Pregnancy: Use is contraindicated during the third trimester of pregnancy (starting at Week 20), as NSAIDs may cause fetal harm, specifically heart and kidney issues.

Restricted or Limited Use

  • Age: The medicine is not approved for use in pediatric patients (under 18 years of age), as safety and efficacy have not been established. Older adult patients may be at a greater risk for adverse effects.
  • Lactation: Use is not recommended in nursing/lactating women.

Official regulatory documents define these mandatory exclusions and restrictions, limiting the use of this medicine to patients who do not present with these specific risks or conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The following documented interaction patterns for Edolar Fort (Etodolac) are based on formal statements from government regulatory authorities. This information details official interaction outcomes and constraints, and is not a guide for usage.

Interaction Category Documented Interacting Substances
Pharmacodynamic Synergy (Risk) Anticoagulants (e.g., Warfarin), other NSAIDs, and Aspirin
Reduced Therapeutic Effect ACE-inhibitors, Diuretics (e.g., Furosemide, Thiazides)
Pharmacokinetic Alteration (Increased Exposure) Lithium, Methotrexate, Digoxin, Cyclosporine, Probenecid

Co-administration with other NSAIDs or Aspirin is not generally recommended due to the officially increased potential for adverse effects. The combination with Warfarin creates a synergistic effect that significantly amplifies the documented risk of serious gastrointestinal bleeding. Furthermore, the label states that Etodolac may officially diminish the antihypertensive effect of ACE-inhibitors and reduce the natriuretic effect of Diuretics.

The interaction with Lithium, Methotrexate, Cyclosporine, and Digoxin is officially associated with reduced renal clearance, which can lead to elevated plasma concentrations and enhanced toxicity of those medicines. The substance Phenylbutazone is documented to cause a significant increase (about 80%) in the free fraction of Etodolac.

Special Constraint Official Regulatory Statement
Timing Separation NSAIDs must not be used for 8 to 12 days following Mifepristone administration, as this may officially reduce the intended effect of Mifepristone.
Food and Antacids Co-administration with food or antacids does not affect the total extent of Etodolac absorption but officially reduces the peak plasma concentration reached.
Alcohol Intake of alcohol (ethanol) officially increases the documented risk of stomach bleeding.

Population-Specific Notes: The profile notes that elderly patients and those with altered renal function may exhibit heightened sensitivity to the antiprostaglandin effects, which can increase the risk associated with these interactions.

Mechanism of Action

Mechanism: Interleukin-6 Receptor Antagonism

Edolar Fort functions as an antagonist of the interleukin-6 ( IL-6) receptor. The molecule binds with high affinity to the receptor, thereby preventing the natural binding of the pro-inflammatory cytokine IL-6. This initial interaction is the foundation of its mechanism.

Intracellular Signaling Pathway Modulation

This blockade prevents the IL-6-mediated upregulation of the RANKL signaling molecule, which subsequently inhibits the activation of osteoclasts. The antagonism also mitigates downstream intracellular cascades, specifically STAT3 and MAPK signaling, resulting in a reduction in the transcription of pro-inflammatory cytokines within the cell.

Physiological Consequence

The resulting decrease in the production of key inflammatory cytokines contributes to a less active inflammatory state at the tissue level. The primary action on the IL-6 pathway modulates both the acute phase response and chronic inflammation across affected systems.

Dosage and Administration Information

How Edolar Fort is Used

Edolar Fort (Etodolac) is administered strictly via the oral route as an oral formulation (tablet or capsule) to produce a systemic effect. Usage instructions define specific dosing schedules and administration conditions to ensure proper use, emphasizing the principle of utilizing the lowest effective dose for the shortest duration.


Official Dosing and Frequency

The maximum recommended daily dose for all formulations of Etodolac is 1200 mg. Dosing varies by the type of product prescribed:

Formulation Typical Dosage Range (Adults) Frequency Maximum Daily Dose
Immediate-Release (IR) 200 mg to 500 mg per dose 2 to 4 times a day (e.g., every 6–8 hours for pain) 1200 mg
Extended-Release (ER) 400 mg to 1000 mg Once daily 1200 mg

Administration Context and Special Handling

Critical instructions regarding how the medicine should be taken include:

  • With Food: Edolar Fort may be taken with or immediately following food to enhance gastrointestinal tolerance. The extent of absorption is not significantly affected by food.
  • Extended-Release (ER) Handling: If prescribed the extended-release tablet, it must be swallowed whole. These tablets must not be crushed, broken, or chewed, as doing so will compromise the integrity of the controlled-release mechanism.

Population Considerations

For older adults (aged 65 and over), specific initial dose reductions are generally not required based on pharmacokinetics; however, caution is advised. Similarly, for patients with mild-to-moderate liver or kidney impairment, specific dose adjustments are typically not mandated, though careful use is advised.

Recent Clinical Evidence

Research evidence / Overview of Studies for Edolar Fort


Evidence for Use in Chronic Inflammatory Conditions

Research exploring Etodolac, the active component in Edolar Fort, was studied for conditions characterized by fluctuating or episodic manifestations, such as osteoarthritis (OA) and rheumatoid arthritis (RA). Studies examining these chronic conditions primarily involve Randomized Controlled Trials (RCTs), where the research included comparisons against other interventions or placebo. The research examined patient-reported outcomes describing perceived discomfort and functional activity level, such as pain intensity at rest and during movement, along with physical signs like joint tenderness and swelling.

These studies were generally designed as intermediate-term trials, lasting between a few weeks and up to three months. Studies monitored patient-reported outcomes reflecting daily functioning, such as stiffness in the morning and limitations in daily activities, and reported changes over the study period. It is important to note that while these trials help contextualize how patients reported their experience, the efficacy assessments for chronic conditions are predominantly based on data from the intermediate term. Long-term clinical outcomes concerning the maintenance of these functional changes beyond the initial follow-up period are not fully established by the existing structured RCTs.

Evidence for Use in Acute Pain

The research base for short-term symptom patterns primarily consists of Controlled Clinical Trials, often with a single-dose or very short-term multiple-dose design. These studies were conducted during periods of increased symptom activity, primarily exploring outcomes linked to acute or disruptive episodes following procedures, such as surgical events, or acute flare-ups of musculoskeletal strains. Studies observed that the measured responses were associated with patterns reported for the active comparator groups included in the same trials.

Known Evidence Gaps and Areas of Uncertainty

The research highlights what is known about Etodolac, but the trial evidence is framed by several limitations.

  • Follow-up durations were limited: The most robust efficacy data for chronic conditions focus on short- to intermediate-term outcomes.
  • Comparative evidence is lacking for certain scenarios: Research comparing Etodolac to all other treatment options for all conditions is not uniformly available.
  • Data for certain groups remain insufficient: While some research has included older adults, there is limited information available on outcomes for other special or complex patient groups.

These evidence limitations highlight what is known, but research does not determine whether an individual will respond similarly, and the findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Clinical Guideline for the Management of Osteoarthritis (NICE Guidance)

Frequently Asked Questions (FAQ)

Common questions about Edolar Fort (FAQ)


Q: How quickly do most patients start to feel the effects of Edolar Fort?

According to official product information, the immediate-release formulation typically has an onset of pain relief noted within 1 to 2 hours of administration. The extended-release formulation is designed to release slowly, resulting in a longer time until the peak concentration is reached.


Q: What is the difference between how Edolar Fort works and similar medications in the same class?

Edolar Fort's active component, Etodolac, belongs to the Non-Steroidal Anti-inflammatory Drug (NSAID) class, but it is chemically classified as a pyranocarboxylic acid derivative. Official product information indicates that the drug's primary action involves the reversible inhibition of cyclooxygenase enzymes, which reduces the body's processes that cause inflammation and pain.


Q: Is feeling dizzy or drowsy a typical side effect when starting Edolar Fort?

Regulatory documents state that dizziness is a common adverse reaction associated with this medication. Other central nervous system effects, such as drowsiness and impaired alertness, are also documented in the safety information. This type of information is usually listed in the official paperwork to inform patients about potential side effects.


Q: What happens if someone experiences a skin rash while taking Edolar Fort?

Regulatory guidance describes that stopping the medication may be necessary if a rash or fever develops, due to the documented risk of serious skin reactions. The safety information emphasizes contacting a healthcare provider immediately if such symptoms occur.


Q: Do any official documents mention Edolar Fort causing changes in appetite or weight?

Regulatory documents list both loss of appetite (anorexia) and abnormal weight changes as potential adverse events in postmarketing reports. Furthermore, unexplained or rapid weight gain is a documented sign of fluid retention, which is a risk factor linked to heart failure noted in the safety warnings.


Q: What food types are described in the official documents as having a potential interaction with Edolar Fort?

According to the official product information, taking Edolar Fort with food or antacids does not affect the total amount of the medicine absorbed by the body. However, taking it with food is documented to reduce the peak concentration reached in the blood plasma. Regulatory documents do not list specific food types that have a dangerous interaction with the medicine.


Q: Does Edolar Fort have known interactions with over-the-counter pain relievers like acetaminophen or ibuprofen?

Official safety information indicates that Edolar Fort is not generally recommended for use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen, due to an increased risk of side effects. However, studies show that the drug’s concentration is not significantly altered by the pain reliever acetaminophen.


Q: Are there any specific vitamins, supplements, or herbal remedies that should be avoided with Edolar Fort?

Official drug interaction databases list potential interactions with certain herbal products that should be noted. These include supplements like American ginseng and alfalfa, which may increase the risk of bleeding or affect how other medications are processed by the body.


Q: Is Edolar Fort considered a habit-forming or controlled substance?

Edolar Fort's active ingredient, Etodolac, is a Non-Steroidal Anti-inflammatory Drug (NSAID) and is not classified as a controlled or habit-forming substance by US regulatory authorities.


Q: What should a patient know if they accidentally miss taking a dose of Edolar Fort?

Regulatory guidance for missed doses describes the general principles of taking the dose as soon as remembered, unless it is close to the time for the next scheduled dose. Official documents also describe that taking a double dose is not advised.


Q: Are there generic versions of Edolar Fort available, according to product information?

The active ingredient, Etodolac, is currently available generically. This includes oral tablet and capsule formulations of the medicine.


Q: How does Edolar Fort affect laboratory test results, if at all?

According to official product information, Etodolac may interfere with the results of certain medical tests. It is specifically documented to interfere with urine tests for ketones. The safety information describes the need for laboratory personnel to be informed about the medication before such testing.


Q: What official information is available about the risk of overdose with Edolar Fort?

Official regulatory documents list that symptoms of an overdose may include lack of energy, drowsiness, nausea, vomiting, and stomach pain. In severe situations, loss of consciousness or seizures are documented. The seriousness of overdose means that regulatory documents describe the need for immediate medical attention in such events.


Q: Is it normal to feel a bit nauseous when taking the first few doses of Edolar Fort?

Nausea is listed in the official documents as a common gastrointestinal adverse reaction for this medication. This information is included to inform patients that it is a documented occurrence.


Q: Is Edolar Fort meant to replace other treatments or be used alongside them?

Studies and official information indicate that Edolar Fort may be used as part of a combination treatment, rather than as a replacement for all other therapies. The safety profile notes that any co-administration requires careful management due to potential documented interactions with other medicines.


Q: Can taking Edolar Fort affect a person's mood?

Regulatory documents list several potential psychiatric adverse events associated with the medicine. These include nervousness and depression, as well as less common events such as confusion and anxiety.

How should Edolar Fort be stored and disposed of?

How to Store and Dispose of Edolar Fort

The storage and disposal requirements for Edolar Fort (Etodolac) are mandated by official regulatory labeling to maintain the product's stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F). Brief excursions between 15 C and 30 C are acceptable.
Protection Keep the medicine protected from moisture and avoid freezing or excessive heat.
Packaging Store in the original container, ensuring the lid or cap remains tightly closed.

The medication must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Edolar Fort must be disposed of according to local regulatory guidelines. The product must not be flushed down a toilet or poured into a drain. Secure disposal is required, often through a drug take-back program or by mixing the medicine into a non-desirable substance before placing it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Edolar Fort found in:

A-Z Index: